125 related articles for article (PubMed ID: 10836745)
1. In vitro cytotoxic effect of N-(phosphonacetyl)-L-aspartic acid in liposome against C-26 murine colon carcinoma.
Kim JS; Heath TD
Arch Pharm Res; 2000 Apr; 23(2):167-71. PubMed ID: 10836745
[TBL] [Abstract][Full Text] [Related]
2. Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers.
Sharma A; Straubinger NL; Straubinger RM
Pharm Res; 1993 Oct; 10(10):1434-41. PubMed ID: 8272404
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2'-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26.
van Laar JA; Durrani FA; Rustum YM
Cancer Res; 1993 Apr; 53(7):1560-4. PubMed ID: 8453623
[TBL] [Abstract][Full Text] [Related]
4. N-(phosphonacetyl)-L-aspartate synergistically enhances the cytotoxicity of 5-fluorouracil/interferon-alpha-2a against human colon cancer cell lines.
Wadler S; Mao X; Bajaj R; Hallam S; Schwartz EL
Mol Pharmacol; 1993 Nov; 44(5):1070-6. PubMed ID: 8246910
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.
Erlichman C; Vidgen D
Biochem Pharmacol; 1984 Oct; 33(20):3177-81. PubMed ID: 6487365
[TBL] [Abstract][Full Text] [Related]
6. PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells.
Yang JL; Fernandes DJ; Wheeler KT; Capizzi RL
Int J Radiat Oncol Biol Phys; 1996 Mar; 34(5):1073-9. PubMed ID: 8600090
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibitory effect of N-(phosphonacetyl)-L-aspartic acid on human myeloid leukemia-derived cell lines and modulation by dipyridamole.
Taguchi H; Kubonishi I; Miyoshi I
Anticancer Res; 1989; 9(4):845-8. PubMed ID: 2817812
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
Chan TC; Howell SB
Cancer Res; 1985 Aug; 45(8):3598-604. PubMed ID: 4016741
[TBL] [Abstract][Full Text] [Related]
9. The role of low-dose PALA in biochemical modulation.
O'Dwyer PJ
Pharmacol Ther; 1990; 48(3):371-80. PubMed ID: 2084707
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of cell growth by N-(phosphonacetyl)-L-aspartate in human and murine cells in vitro.
Leyva A; Appel H; Smith P; Lankelma J; Pinedo HM
Cancer Lett; 1981 Mar; 12(1-2):169-73. PubMed ID: 7273001
[TBL] [Abstract][Full Text] [Related]
12. Effect of N-(phosphonacetyl)-L-aspartate on 5-azacytidine metabolism in P388 and L1210 cells.
Grant S; Rauscher F; Jakubowski A; Cadman E
Cancer Res; 1981 Feb; 41(2):410-8. PubMed ID: 6160908
[TBL] [Abstract][Full Text] [Related]
13. Embryotoxicity in mice of phosphonacetyl-L-aspartic acid (PALA), a new antitumor agent. I. Embryolethal, teratogenic, and cytogenetic effects.
Sieber SM; Botkin CC; Soong P; Lee EC; Whang-Peng J
Teratology; 1980 Dec; 22(3):311-9. PubMed ID: 7233336
[TBL] [Abstract][Full Text] [Related]
14. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Erlichman C; Donehower RC; Speyer JL; Klecker R; Chabner BA
J Natl Cancer Inst; 1982 Feb; 68(2):227-31. PubMed ID: 6950156
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of S-acyl-3-thiopropyl prodrugs of N-phosphonoacetyl-L-aspartate (PALA).
Gagnard V; Leydet A; Le Mellay V; Aubenque M; Morère A; Montero JL
Eur J Med Chem; 2003 Oct; 38(10):883-91. PubMed ID: 14575935
[TBL] [Abstract][Full Text] [Related]
16. Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
Chan TC; Markman M; Cleary S; Howell SB
Cancer Res; 1986 Jun; 46(6):3168-72. PubMed ID: 3698032
[TBL] [Abstract][Full Text] [Related]
17. Unexpected synergy between N-phosphonacetyl-L-aspartate and cytidine against human tumor cells.
Chan TC; Howell SB
Eur J Cancer Clin Oncol; 1989 Apr; 25(4):721-7. PubMed ID: 2714348
[TBL] [Abstract][Full Text] [Related]
18. Modulation of the antitumour activity of cisplatin alone and in combination with 5-fluoro-2'-deoxyuridine by N-phosphonacetyl-L-aspartate in murine colon carcinoma no. 26.
Van Laar JA; Mayhew EG; Cao S; Durrani FA; Peters GJ; Rustum YM
Eur J Cancer; 1995 Jun; 31A(6):974-6. PubMed ID: 7646931
[TBL] [Abstract][Full Text] [Related]
19. A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.
Jodrell DI; Oster W; Kerr DJ; Canney PA; Yosef H; Steward WP; Kaye SB; Cassidy J
Eur J Cancer; 1994; 30A(7):950-5. PubMed ID: 7946590
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance.
Martin DS; Stolfi RL; Sawyer RC; Spiegelman S; Casper ES; Young CW
Cancer Res; 1983 May; 43(5):2317-21. PubMed ID: 6187448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
